Loading company…
Riskpilot
← Back to search
Sign in
Get full access
ENZYFERM AS
AS
Active
Org 932763737
Holsetgata 22, 2317 Hamar
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2024
0 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 690K
EBITDA margin
-185.0%
Equity ratio
-18.3%
Financial strength
Net profit 2024
NOK -1,3M
0 employees
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2023
-1M
-100%
2024
Key figures
Annual report 2024
Revenue
NOK 690K
—
EBITDA
NOK -1,3M
—
Net profit
NOK -1,3M
—
Total assets
NOK 1,6M
+5351%
Equity
NOK -299K
-1325%
Employees
0
—
Company information
Legal name
ENZYFERM AS
Org number
932763737
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12. januar 2024
Share capital
NOK 1 030 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Utvikle, selge og markedsføre teknologi og produkter basert på mikrobiologisk materiale.
Contact
Address
Holsetgata 22, 2317 Hamar
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Hamar
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2023
1M
2024
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2023
-1M
2024
Income statement
NOK thousands
Item
2023
2024
Revenue
0
690
Staff expenses
−0
−871
EBITDA
0
−1 277
Depreciation & amort.
−0
−17
EBIT
0
−1 294
Net financials
0
−30
Profit before tax
0
−1 324
Tax
−0
−0
Net profit
0
−1 324
Balance sheet
NOK thousands
Item
2023
2024
Total assets
30
1 635
Equity
24
−299
Long-term debt
0
1 026
Short-term debt
6
909
Total debt
6
1 934
Financial ratios
5-year trend
EBITDA margin
-185.0%
This company
15.8%
Market median
-1271% vs market
2023
2024
Equity ratio
-18.3%
This company
38.2%
Market median
-148% vs market
2023
2024
Return on equity
-132370800.0%
This company
18.4%
Market median
-719406622% vs market
2023
2024
Net profit margin
-191.7%
This company
8.1%
Market median
-2467% vs market
2023
2024
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
2023
2024
Debt / equity
6.46×
This company
0.62×
Market median
-942% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-12-21 – 2023-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (3)
LC
Leif Christian Hanstad
Chairman
2024
SS
Siavash Seifollahy Fakhr
Board of Directors
2024
ØB
Øystein Bakken Vold
Chairman
2024
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Fbv Holding As
Company
34.16%
34.16%
2023
Griselda As
Company
34.16%
34.16%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Fbv Holding As
ENZYFERM AS
(this company)
Board network connections
Board members of ENZYFERM AS also hold positions in
0
other companies.
Person
Role here
Other companies
Leif Christian Hanstad
Chairman
0 companies
Siavash Seifollahy Fakhr
Board of Directors
0 companies
Øystein Bakken Vold
Chairman
0 companies